239 reports of this reaction
2.5% of all EDOXABAN TOSYLATE reports
#6 most reported adverse reaction
CEREBRAL INFARCTION is the #6 most commonly reported adverse reaction for EDOXABAN TOSYLATE, manufactured by Daiichi Sankyo Inc.. There are 239 FDA adverse event reports linking EDOXABAN TOSYLATE to CEREBRAL INFARCTION. This represents approximately 2.5% of all 9,635 adverse event reports for this drug.
Patients taking EDOXABAN TOSYLATE who experience cerebral infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBRAL INFARCTION is a less commonly reported adverse event for EDOXABAN TOSYLATE, but still significant enough to appear in the safety profile.
In addition to cerebral infarction, the following adverse reactions have been reported for EDOXABAN TOSYLATE:
The following drugs have also been linked to cerebral infarction in FDA adverse event reports:
CEREBRAL INFARCTION has been reported as an adverse event in 239 FDA reports for EDOXABAN TOSYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBRAL INFARCTION accounts for approximately 2.5% of all adverse event reports for EDOXABAN TOSYLATE, making it a notable side effect.
If you experience cerebral infarction while taking EDOXABAN TOSYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.